Clinical Trial Details
— Status: Suspended
Administrative data
| NCT number |
NCT02742883 |
| Other study ID # |
BRI-BT-55 |
| Secondary ID |
|
| Status |
Suspended |
| Phase |
Phase 2
|
| First received |
|
| Last updated |
|
| Start date |
April 13, 2016 |
| Est. completion date |
March 2028 |
Study information
| Verified date |
March 2023 |
| Source |
Burzynski Research Institute |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Interventional
|
Clinical Trial Summary
Current therapies for diffuse, intrinsic pontine glioma (DIPG) provide very limited benefit
to the patient. The rationale for the use of Antineoplaston therapy in this protocol study
derives from experience with subjects from prior Phase 2 studies and Compassionate Exemption
patients treated with Antineoplaston therapy at the Burzynski Clinic.
This study is designed to analyze the efficacy and safety of Antineoplaston therapy in five
separate DIPG patient cohorts, which are defined by age and prior therapy. This is a two
stage study with 20 patients in each cohort being enrolled in the first stage and an
additional 20 patients being enrolled in the second stage, if pre-determined efficacy
endpoints in the first stage are realized.
Description:
This study is designed to analyze the response of diffuse, intrinsic brainstem glioma (DIPG)
to Antineoplaston therapy in 5 separate patient cohorts, which are defined by age and prior
therapy. The primary endpoint is objective response (OR), but the determination of OR in DIPG
is problematic. Determination of OR using the Macdonald, RANO, and RECIST criteria relies on
postgadolinium TI-weighted MRI images of enhancing disease. However, DIPG shows variable
enhancement and has a non-enhancing component as seen on T2/FLAIR-weighted MRI images. Recent
reviews have proposed OR assessment in diffuse low grade gliomas using modified RANO criteria
and in recurrent glioblastoma using RECIST + F (T2/FLAIR-weighted images).Neither of these
methodologies have been validated.
This single-arm Phase 2 study of the efficacy of Antineoplaston therapy in DIPG will utilize
both bidimensional assessment of enhancing DIPG (RANO), a validated primary endpoint, and
unidimensional assessment of enhancing + non-enhancing DIPG (RECIST + F), an exploratory
endpoint.
This Phase 2 protocol has a strategy for early assessment of response rates with procedures
for termination of enrollment for lack of efficacy. A minimax two-stage design is utilized.
Ten patients with enhancing disease will be enrolled in stage 1 for each cohort. If none of
the 10 patients in a particular cohort achieves an OR based on bidimensional measurements, no
additional patients with enhancing disease will be enrolled into that particular cohort.
However, if 1 of the 10 patients with enhancing disease in a particular cohort achieves an
OR, then an additional 10 patients with enhancing disease will be enrolled in stage 2 of the
minimax design for that cohort, yielding a maximum of 20 patients with enhancing disease for
that cohort. As exploratory endpoints, complete response (CR), partial response (PR), and
progressive disease (PD) rates, as well as 6-, 12-, and 24-month overall survival (OS) will
be analyzed.
Patients with no enhancing disease will also be enrolled into each cohort but will not count
against the numbers designated in the two-stage minimax design. An exploratory endpoint for
these patients will be 6-, 12-, and 24-month OS.
Other exploratory endpoints will be determination of OR, CR, PR, and PD based on
unidimensional measurement of the enhancing + non-enhancing components of DIPG (RECIST + F).
At completion of this study, the efficacy of Antineoplaston therapy in each cohort and the
desirability of its further development in any particular cohort will be determined in
discussion with the FDA.
